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Abstract
The degradation of proteins by asparagine deamidation and aspartate isomerization is one of several chemical degradation
pathways for recombinant antibodies. In this study, we have identified two solvent accessible degradation sites (light chain
aspartate-56 and heavy chain aspartate-99/101) in the complementary-determining regions of a recombinant IgG1 antibody
susceptible to isomerization under elevated temperature conditions. For both hot-spots, the degree of isomerization was
found to be significantly higher than the deamidation of asparagine-(387, 392, 393) in the conserved CH3 region, which has
been identified as being solvent accessible and sensitive to chemical degradation in previous studies. In order to reduce the
time for simultaneous identification and functional evaluation of potential asparagine deamidation and aspartate
isomerization sites, a test system employing accelerated temperature conditions and proteolytic peptide mapping
combined with quantitative UPLC-MS was developed. This method occupies the formulation buffer system histidine/HCl
(20 mM; pH 6.0) for denaturation/reduction/digestion and eliminates the alkylation step. The achieved degree of asparagine
deamidation and aspartate isomerization was adequate to identify the functional consequence by binding studies. In
summary, the here presented approach greatly facilitates the evaluation of fermentation, purification, formulation, and
storage conditions on antibody asparagine deamidation and aspartate isomerization by monitoring susceptible marker
peptides located in the complementary-determining regions of recombinant antibodies.
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Introduction
Degradation of proteins by asparagine (Asn) deamidation and
aspartate (Asp) isomerization has been extensively reviewed
[1,2,3,4,5,6]. Previous studies have identified that degradation of
Asn and Asp residues in proteins can impact in vivo biological
functions and in vitro stability [7,8,9,10,11]. Recombinant
monoclonal antibodies (mAbs) are exposed to process and storage
conditions that might influence the rate of deamidation and
isomerization. Cacia et al. demonstrated that the light chain Asp-
32 of an anti-IgE antibody could be converted to a succinimide
intermediate (Asu) and iso-aspartate (iso-Asp) [9]. Three IgG1
mAbs have been reported to lose activity because of deamidation
or isomerization in the complementary-determining regions
(CDRs) of the heavy chain [12,13,14]. In case of the recombinant
IgG1 antibody Herceptin (HER2), the loss of potency was caused
by the isomerization of heavy chain Asp-102 (CDR 3).
Deamidation of the light chain Asn-30 (CDR 1) did not
significantly impact the HER2 potency [12]. Two independent
studies reported the heavy chain Asn-55 (CDR 2) to be susceptible
to deamidation in vivo [13] and to exist in a stable succinimide form
at mildly acidic pH [14]. In another investigation, the light chain
Asp-30 of an IgG2 antibody was found to form succinimide and
iso-Asp. However, no significant impact on the biological function
was reported [15]. Chelius et al. applied accelerated degradation
conditions to identify four potential deamidation sites in the
conserved regions of recombinant IgG1 monoclonal antibodies
[16].
Analytical characterization of Asn deamidation and Asp
isomerization has been conducted by enzymatic methylation
[17,18], chemical hydrolysis with hydroxylamine [19], by chro-
matographic fractionation followed by Edman sequencing, and
tryptic digestions [9,15,20]. Approaches involving mass spectrom-
etry provide alternative solutions for the characterization of
deamidation and isomerization events. Advances in high resolution
mass spectrometry has enabled the analysis of Asn deamidation in
intact proteins [21,22,23,24]. However, for large biomolecules such
as recombinant antibodies, bottom-up liquid chromatography-mass
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30295spectrometry (LC-MS) of proteolytic peptides is often the method of
choice for monitoring site specific deamidation or isomerization
reactions [13,14,15,16,25,26,27,28,29].
In the present study, an approach employing elevated
temperatures and proteolytic peptide mapping combined with
quantitative LC-MS for the simultaneous induction, identification
and quantification of Asn deamidation and Asp isomerization in
recombinant antibodies was developed. This test system allowed us
to identify light chain Asp-56 (CDR 2) and heavy chain Asp-99/
101 (CDR 3) as potential sites for Asp isomerization in
recombinant IgG1 antibodies.
Results
The developed test system for the simultaneous identification and
quantification of Asn deamidation and Asp isomerization in
recombinant antibodies employs proteolytic peptide mapping at
mildly acid conditions combined with quantitative UPLC-MS. In
general, the new method (procedure B) involves denaturation and
reduction at pH 6.0 leaving out any alkylation step, followed by
proteolytic digestion also at pH 6.0 in histidine/HCl (Figure 1). To
demonstrate that the developed sample preparation procedure
significantly reduces method-induced Asn deamidation, reference
material (stored at 280uC) of the recombinant IgG1 antibody
HER2 was analyzed according to the sample preparation
procedures A and B depicted in Figure 1. The extent of quantifiable
Asn deamidation and Asp isomerization was determined by
quantitative evaluation of specific ion current chromatograms of
modified LysC peptides and their unmodified parent peptides using
the quantification software GRAMS/32 (Table 1). For all light or
heavychainAsnresiduesthe applicationofthe procedureB resulted
in a significant reduction of method-induced deamidation events
(Table 1; 29% up to 94%). In addition, the Asu content was
stabilized for all monitored Asn and Asp residues as a consequence
of the mild acid conditions (Tables 1, 2, 3). Moreover, the HER2
LysC peptide containing the HC-iso-Asp-102 was only chromato-
graphically resolved after applying procedure B.
To assess potential sites for HER2 degradation, we exposed
HER2 reference material to elevated temperature conditions (25uC
and 40uC) for up to 2 month followed by LysC peptide mapping
according to procedure B combined with quantitative UPLC-MS.
Table 2 summarizes the quantification results for those HER2
amino acid residues that showed significant alterations in Asn
deamidation or Asp isomerization. For LC-Asn-30 (located in the
CDR 1) we found significantly increased levels of Asu, Asp, and iso-
Asp at both temperatures. The appearance of around 25% LC-Asu
after 2 months at 40uC was further demonstrated by off-line
electrospray ionization mass spectrometry (ESI-MS) of reduced
HER2 material where a loss of 17 Da was only observed for the
antibody LC of stressed HER2 material (Figure 2). In contrast, the
Asu level of HC-Asn-55 (located in the CDR 2) was not affected by
the elevated temperatures and only a moderate increase in
deamidation (3.6% to 8.9%) was observed at 40uC after 2 month
(Table 2). The HC-Asp-102 (located in the CDR 3) displayed a
demonstrative elevation in iso-Asp formation upon application of
temperature stress (from 2.5% up to 46.1% after 2 M incubation at
40uC); however, only a minimal increase of the HC-Asu-102 level
was detected (Table 2). For the HC-Asp-283 and HC-Asn-(387,
392, 393), both located in the conserved region of recombinant
IgG1 antibodies, no significant changes in Asu formation, but a
moderate increase of iso-Asp and Asp/iso-Asp formation, respec-
tively, was observed following incubation at 40uC. Consequently,
thesignificantalterationsinAsndeamidation and Aspisomerization
upon temperature stress resulted in significant changes of HER2
charge variants (determined by cation-exchange chromatography,
Table 2). However, the preservation of structural integrity was
verified by size-exclusion chromatography analysis where only a
minimal increase of fragment or aggregate formation could be
demonstrated (Table 2). Moreover, the increase of Asn deamidation
and Asp isomerization lead to a significant loss of target binding
activity. A previous study has already identified LC-Asn-30 and
HC-Asp-102 as potential sites for HER2 degradation and the
criticality of HC-iso-Asp-102 formation for HER2 potency was
demonstrated [12].
Figure 1. Overview of sample preparation procedures A and B for the UPLC-MS analysis of antibody Asn deamidation and Asp
isomerization.
doi:10.1371/journal.pone.0030295.g001
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quantitative UPLC-MS and binding studies was adequate to assess
potential sites for HER2 Asn deamidation and Asp isomerization.
Next, we employed the described approach to identify critical
quality attributes (CQAs) for an IgG1 in early clinical development
(Mab1). Mab1 shares with HER2 the LC-Asn-30 in the CDR 1
and offers a HC-Asp-99/Gly-100/Asp-101 motive in the CDR 3.
Moreover, Mab1 exhibits a novel LC-Asp-56/Gly-57 motive in
the CDR 2 (Figure 3). Following incubation of Mab1 at elevated
temperatures, a significant increase of basic charge variants were
observed, whereas only a slight increase of acidic charge variants
could be detected (Figure 4, Table 3). In addition, ESI-MS analysis
of reduced Mab1 material indicated a loss H2O( 218 Da) for the
antibody light and heavy chain (Figure 5) of stressed Mab1
material. In conclusion, the data suggest a significant formation of
Asu and only a minor formation of Asp. Next, the stressed samples
were analyzed by LysC peptide mapping combined with
quantitative UPLC-MS. The LysC peptide mapping approach
resulted in the identification of distinct Asu and moderate iso-Asp
formation at HC-Asp-99/Asp-101 (Figure 6, Table 3). In addition,
a moderate elevation of deamidation at the conserved HC-Asn-
(389, 394, 395) was observed (Table 3). However, due to
inadequate chromatographic separation of the generated LysC
peptides it was not possible to relatively quantify the amount of
deamidation at LC-Asn-30 and the isomerization at LC-Asp-56.
Therefore, procedure B and tryptic peptide mapping was applied
to generate shorter Mab1 peptides. The tryptic peptide mapping
approach demonstrated minimal deamidation at LC-Asn-30 but
significant Asu and iso-Asp formation at LC-Asp-56 (Figure 7,
Table 3). Moreover, massive formation of iso-Asp was observed at
HC-Asp-99/Asp-101 which is in contrast to the results from ESI-
MS analysis and LysC peptide mapping which both suggest the
primary formation of Asu instead of iso-Asp (Figure 5, Table 3).
This observation is most likely due to the N-terminal location of
the HC-Asp-99/Gly-100/Asp-101 motive at tryptic peptide level
(see tryptic cleavage site HC-Arg-98 in Figure 3) which likely
promotes the conversion of Asu to iso-Asp. Thus, the demonstra-
tive iso-Asp formation at HC-Asp-99/Asp-101 of the tryptic
peptide is regarded a method artifact.
Sequence determination of all LysC/tryptic Mab1 peptides
selected for quantitative evaluation of deamidation and isomeri-
zation events was carried out on-line by low-energy CID
(exemplarily shown for the tryptic peptide containing LC-Asu-
56, Figure 8). Interestingly, the Asu formation at LC-Asp-56 seems
to block the generation of nearby C-terminal fragment ions (y4 and
y5) and was not resolvable by variation of the low-energy CID
conditions. This phenomena was already described in a recently
published study on Asu formation at LC-Asp-30 of an IgG1
antibody [30].
Comparable with HER2, the elevated Asu formation in the
CDR lead to a significant loss of target binding activity of Mab1
(Figure 9, Table 3).
Discussion
For the identification of antibody CQAs derived from Asn
deamidation and Asp isomerization events, a test system was
applied employing incubation at elevated temperatures combined
with proteolytic peptide mapping and quantitative UPLC-MS.
The application of the histidine/HCl buffer system at pH 6.0
resulted in a significant reduction of method-induced deamidation
events and the stabilization of Asu. For the recombinant IgG1
HER2 only 5 out of 14 LysC peptides containing Asn residues
were found deamidated at quantifiable levels. Moreover, by
applying UPLC-MS it was possible to monitor all relevant
deamidated or isomerized LysC/tryptic peptide species. Although
LysC/trypsin has optimal operating pH of about 8 and LysC/
trypsin in this study was applied to pH 6.0, we obtained almost
complete sequence coverages of $98% for HER2 and MAb1 by
LC-MS and routinely find similar sequence coverages for other
mAbs using Procedure B (data not shown). Also the reducing
power of DTT is optimal at pH.7. In this study, we exclusively
used DTT at pH 6.0 without the finding of significant di-peptide
levels caused by incomplete sample reduction. It should be noted
that ionization efficiencies of peptides can differ significantly
depending on their amino acid contents. Increasing hydrophobic-
ity usually leads to an enhanced formation of ionic species. On the
other hand also variation of the pI value of peptides also alters the
ionization efficiency. Consequently, different ionization efficiencies
have to be taken into account when discussing and interpreting the
data obtained from the presented experiments. However, the
detected levels of deamidated or isomerized LysC/tryptic peptide
Table 1. Comparison of the pH 7.0 (procedure A) and pH 6.0
(procedure B) sample preparation procedures for the UPLC-
MS analysis of HER2 Asn deamidation and Asp isomerizations.
Procedure A Procedure B
LC-Asn-30
LC-Asu-30 n.d. 2.6
LC-Asp-30 1.2 0.4
LC-iso-Asp-30 13.5 7.5
HC-Asn-28
HC-Asu-28 n.d. n.d.
HC-deamid-28 5.0 n.d.
HC-Asn-55
HC-Asu-55 4.7 5.6
HC-deamid-55 29.9 3.6
HC-Asp-102
HC-Asu-102 1.8 2.1
HC-iso-Asp-102 n.q. 2.5
HC-Asp-283
HC-Asu-283 4.1 4.8
HC-iso-Asp-283 1.6 0.9
HC-Asn-364
HC-Asu-364 0.2 0.1
HC-deamid-364 7.4 1.7
HC-Asn-387,392,393
HC-Asu-387,392,393 6.3 0.7
HC-deamid-387,392,393 9.8 0.3
HC-Asp-404
HC-Asu-404 2.2 3.8
HC-iso-Asp-404 n.d. n.d.
HC-Asn-424,437
HC-Asu-424,437 n.d. n.d.
HC-deamid-424,437 12.9 8.0
Relative quantification (in %) was conducted by specific ion current
chromatogram analysis of proteolytic LysC peptides using the quantification
software GRAMS/32
TM. deamid, total Asp/iso-Asp; n.d., not detectable; n.q., not
quantifiable.
doi:10.1371/journal.pone.0030295.t001
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chromatography, ESI-MS of reduced antibody, and target binding
analysis suggesting that the depicted deamidation and isomeriza-
tion content is not significantly overestimated for the inspected
peptide species.
The application of elevated temperature stress (25uC and 40uC)
for the CQA assessment resulted in the identification of LC-Asn-
30, HC-Asn-55, and HC-Asp-102 as potential HER2 degradation
hot-spots. These results are in agreement with a previous study on
HER2 charge variants [12], in which LC-iso-Asp-30 was found as
a predominant degradation product of LC-Asn-30 following
incubation at 30uC for 90 days and using a conventional digestion
procedure at pH 7.5. However, we found a significant accumu-
lation of LC-Asu-30 at both temperature conditions. This again
demonstrates that proteolytic peptide mapping with procedure B
stabilizes the Asu content by preventing method-induced conver-
sion of Asu to Asp and iso-Asp at peptide level. This conclusion is
supported by a recently published study on Asu formation at LC-
Asp-30 of an IgG1 antibody where the Asu conversion to iso-Asp
was minimized by a tryptic digestion at pH 7 for 1 h [30].
Chelius et al. identified HC-Asn-(387, 392, 393) as most
susceptible deamidation motive in the conserved region of
recombinant IgG1s [16]. However, for the HC-Asp-283 (features
a Gly-Asp motive like HC-Asp-102) and HC-Asn-(387, 392, 393)
of HER2 no significant alterations in Asu accumulation and only a
moderate increase of Asp and iso-Asp formation was observed
following incubation at 40uC for 2 month. In conclusion, the level
of degradation was around 5 to 10 times lower than the detected
levels at LC-Asn-30 and HC-Asp-102.
The described approach was employed to identify CQAs for the
Mab1 IgG1. Mab1 shares with HER2 the LC-Asn-30, offers a
HC-Asp-99/Gly-100/Asp-101 motive, and exhibits a novel LC-
Asp-56/Gly-57 sequence in the CDR 2. In contrast to HER2, only
minimal Asu accumulation and deamidation at Mab1 LC-Asn-30
was verified, suggesting that the differences in neighboring amino
acid residues administrate a protective effect. Contrary to HER2,
we found a distinct Asu but only a moderate iso-Asp formation of
Mab1 HC-Asp-99/Asp-101. Nevertheless, the elevated Asu
formation in the CDR 3 also led to a significant loss of target
binding activity. In addition, significant Asu and iso-Asp formation
of Mab1 LC-Asp-56 was demonstrated. Since Asu/iso-Asp
generation at LC-Asp-56 coexists with higher levels of Asu/iso-
Asp formation at HC-Asp-99/Asp-101, the impact of LC-Asp-56
degradation on bioactivity cannot be unambiguously evaluated.
Table 2. Assessment of HER2 Asn deamidation and Asp isomerization using accelerated degradation conditions and quantitative
UPLC-MS (Procedure B).
Storage Duration/Temperature RM/806C 1 M/256C 2 M/256C 7 d/406C 1 M/406C 2 M/406C
LC-Asn-30
LC-Asu-30 2.6 (60.2) 9.0 (60.3) 11.0 (60.8) 12.5 (60.3) 23.4 (61.8) 24.8 (61.7)
LC-Asp-30 0.4 (60.1) 2.1 (60.1) 3.1 (60.1) 3.2 (60.2) 4.7 (60.1) 7.0 (60.6)
LC-isoAsp-30 7.5 (60.7) 10.9 (60.4) 15.3 (61.1) 11.1 (61.1) 18.8 (62.6) 26.5 (60.2)
HC-Asn-55
HC-Asu-55 5.6 (60.4) 5.5 (60.7) 5.1 (60.9) 5.5 (60.4) 5.2 (60.4) 5.4 (60.6)
HC-deamid-55 3.6 (60.4) 4.1 (60.1) 3.8 (60.6) 4.3 (60.1) 5.4 (60.5) 8.9 (61.1)
HC-Asp-102
HC-Asu-102 2.1 (60.2) 2.8 (60.1) 2.8 (60.1) 3.4 (60.1) 3.1 (60.4) 3.8 (60.1)
HC-isoAsp-102 2.5 (60.4) 9.0 (60.5) 15.9 (60.6) 14.6 (60.2) 25.9 (61.2) 46.1 (61.0)
HC-Asp-283
HC-Asu-283 4.8 (60.6) 5.2 (60.7) 5.7 (61.0) 5.9 (61.3) 5.8 (60.1) 5.6 (60.5)
HC-isoAsp-283 0.9 (60.1) 1.0 (60.1) 1.3 (60.3) 1.3 (60.2) 2.1 (60.1) 3.4 (60.1)
HC-Asn-387,392,393
HC-Asu-387,392,393 0.7 (60.1) 0.7 (60.1) 1.0 (60.1) 0.8 (60.1) 0.9 (60.1) 0.9 (60.1)
HC-deamid-387,392,393 0.3 (60.1) 0.8 (60.1) 1.4 (60.4) 1.0 (60.1) 1.8 (60.1) 3.8 (60.1)
CEC
% Acidic 27.7 32.7 39.8 33.7 46.7 n.q.
% Main 63.5 51.3 38.5 45.0 26.0 n.q
% Basic 8.8 16.0 21.6 21.3 27.3 n.q
SEC
% Fragment ,0.1 0.1 0.2 0.2 0.4 1.0
% Monomer 99.8 99.6 99.4 99.4 99.0 98.2
% Aggregate 0.2 0.3 0.4 0.4 0.6 0.8
SPR
% Target Binding 100 (62) 93 (62) 89 (62) 90 (62) 79 (62) 59 (63)
Relative quantification (in %) was conducted by specific ion current chromatogram analysis of proteolytic LysC peptides using the quantification software GRAMS/32
TM
(n=2, mean 6 S.D). HER2 charge variants were monitored by cation-exchange chromatography (CEC). Formation of fragments and aggregates was monitored by size-
exclusion chromatography (SEC) and target binding activity was assessed by SPR-analysis. deamid, total Asp/iso-Asp; n.q., not quantifiable; RM, Reference material.
doi:10.1371/journal.pone.0030295.t002
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elevated when compared to the conserved HC-Asn-(389, 394, 395)
motive. The criticality of Asu formation at HC-Asn-55 for target
binding activity was described in a previous study [14]. Thus,
Asu/iso-Asp formation at HC-Asp-99/Asp-101 and LC-Asp-56
can be regarded as Mab1 CQAs.
In summary, the application of elevated temperatures combined
with LysC/tryptic peptide mapping at pH 6.0 and quantitative
UPLC-MS was adequate to identify and assess potential sites for
antibody Asp isomerization and Asn deamidation. Accordingly,
the evaluation of fermentation, purification, formulation, and
storage conditions on antibody Asn deamidation and Asp
Table 3. Identification and evaluation of Mab1 Asn deamidation and Asp isomerization sites using accelerated degradation
conditions and quantitative UPLC-MS (Procedure B).
Storage Duration/Temperature RM/806C 1 M/256C 2 M/256C 7 d/406C 1 M/406C 2 M/406C
LC-Asn-30
LC-Asu-30 n.q. n.q. n.q. n.q. n.q. n.q.
LC-deamid-30 n.q. n.q. n.q. n.q. n.q. n.q.
(LysC digestion)
LC-Asp-56
LC-Asu-56 n.q. n.q. n.q. n.q. n.q. n.q.
LC-isoAsp-56 n.q. n.q. n.q. n.q. n.q. n.q.
(LysC digestion)
HC-Asp-99/101
HC-Asu-99/101 9.1 (61.1) 16.2 (61.4) 19.8 (61.3) 19.9 (60.5) 32.0 (60.6) 38.2 (60.4)
HC-isoAsp-99/101 n.q. n.q. n.q. n.q. n.q. n.q.
(LysC digestion)
LC-Asn-30
LC-Asu-30 0.3 (60.1) 0.3 (60.1) 0.4 (60.1) 0.5 (60.1) 0.7 (60.1) 0.9 (60.1)
LC-deamid-30 3.4 (61.4) 3.1 (60.9) 3.2 (61.0) 3.1 (61.5) 3.4 (62.0) 4.2 (61.4)
(Trypsin digestion)
LC-Asp-56
LC-Asu-56 6.2 (60.8) 8.5 (61.1) 9.4 (61.5) 9.5 (60.7) 11.9 (60.3) 12.6 (60.6)
LC-isoAsp-56 2.3 (60.4) 3.9 (61.1) 5.5 (61.3) 4.5 (61.2) 9.0 (61.2) 11.3 (61.3)
(Trypsin digestion)
HC-Asp-99/101
HC-Asu-99/101 2.9 (60.1) 4.7 (60.4) 5.1 (60.4) 4.9 (60.6) 6.0 (60.6) 6.7 (60.6)
HC-isoAsp-99/101 9.4 (60.1) 17.6 (60.3) 22.1 (60.1) 21.4 (60.1) 40.0 (60.3) 55.6 (60.8)
(Trypsin digestion)
HC-Asn-389,394,395
HC-Asu-389,394,395 0.8 (60.1) 0.8 (60.1) 0.8 (60.1) 0.9 (60.1) 0.9 (60.1) 0.9 (60.1)
HC-deamid-389,394,395 2.1 (60.2) 2.1 (60.2) 2.3 (60.1) 3.2 (60.1) 3.2 (60.1) 4.3 (60.1)
(LysC digestion)
CEC
% Acidic 18.6 17.1 19.1 16.4 17.6 22.7
% Main 59.7 45.3 36.9 37.7 21.1 17.3
% Basic 21.7 37.6 44.0 45.9 61.3 60.0
SEC
% Fragment ,0.1 ,0.3 0.3 ,0.3 0.5 5.4
% Monomer 98.7 98.5 98.4 98.6 98.1 92.7
% Aggregate 1.3 1.3 1.3 1.2 1.4 1.9
SPR
% Target Binding 100 (62) 90 (62) 83 (61) 85 (62) 53 (62) 22 (61)
Relative quantification (in %) was conducted by specific ion current chromatogram analysis of proteolytic peptides (LysC or trypsin) using the quantification software
GRAMS/32
TM (n=2, mean 6 S.D). MAB1 charge variants were monitored by cation-exchange chromatography (CEC). Formation of fragments and aggregates was
monitored by size-exclusion chromatography (SEC) and target binding activity was assessed by SPR-analysis. deamid, total Asp/iso-Asp; n.q., not quantifiable; RM,
Reference material.
doi:10.1371/journal.pone.0030295.t003
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30295Figure 2. ESI-QTOF mass spectrometry of reduced HER2. NanoESI-QTOF mass spectra of HER2 reference material and HER2 stressed sample
(stored at 40uC for 2 month). The spectra were recorded in the positive ion mode using acetonitrile/water/formic acid (78/20/2, v/v/v) as solvent. LC,
light chain; HC-G0, non-galactosylated heavy chain; HC-G1, mono-galactosylated heavy chain.
doi:10.1371/journal.pone.0030295.g002
Figure 3. Partial sequences of HER2 and Mab1.
doi:10.1371/journal.pone.0030295.g003
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PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e30295Figure 4. Cation-exchange chromatography of Mab1 reference material versus selected stressed samples (stored at 406C; 7 days, 1
and 2 month).
doi:10.1371/journal.pone.0030295.g004
Figure 5. ESI-QTOF mass spectrometry of reduced Mab1. NanoESI-QTOF mass spectra of Mab1 reference material and Mab1 stressed sample
(stored at 40uC for 2 month). The spectra were recorded in the positive ion mode using acetonitrile/water/formic acid (79/20/1, v/v/v) as solvent. LC,
light chain; HC-G0, non-galactosylated heavy chain; HC-G1, mono-galactosylated heavy chain.
doi:10.1371/journal.pone.0030295.g005
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peptides located in the CDRs of recombinant IgG1 antibodies.
Materials and Methods
Induction of Asn deamidation and Asp isomerization
using accelerated degradation conditions
The recombinant IgG1 antibodies HER2 and Mab1 were
expressed in a Chinese hamster ovary cell system. Both antibodies
were manufactured at Roche Diagnostics, Penzberg, Germany
using standard cell culture and purification technology. HER2 was
formulated at a concentration of 25 mg/mL in a His-HCl buffer
system (60 mM) at pH 6.0. Mab1 was formulated at a concen-
tration of 10 mg/mL in a His-HCl buffer system (20 mM) at
pH 6.0. To induce antibody Asn deamidation and Asp isomer-
ization, the recombinant IgG1 antibodies HER2 and MAB1 were
exposed to elevated temperatures (25uC and 40uC) for 7 days, 1
month, or 2 month.
Proteolytic digest (Procedure B)
For the detection and quantification of Asn deamidation and
Asp isomerization at peptide level, HER2 and Mab1 were
denatured in 0.2 M His-HCl, 8 M Gua-HCl, pH 6.0 by diluting
350 mg of mAb in a total volume of 300 mL. For reduction, 10 ml
of 0.1 g/mL dithiothreitol was added followed by incubation at
50uC for 1 hour. As a next step, the buffer solution was exchanged
to a digestion buffer (0.02 M His-HCl, pH 6.0) using a NAP5H-gel
filtration column (GE Healthcare, Buckinghamshire, UK). Subse-
quently, the NAP5H-eluate (500 mL) was mixed with 10 mLo fa
0.25 mg/mL trypsin solution (Trypsin Proteomics grade, Roche,
Penzberg, Germany) in 10 mM HCl or with 10 ml of a 0.25 mg/
mL Lys-C solution (Endoproteinase Lys-C Sequenzing Grade,
Roche, Penzberg, Germany) in water and incubated at 37uC for
18 (Procedure B). Procedure A sample preparation was carried out
according to the method described by Hensel et al. [31].
Analysis of proteolytic peptides by liquid-
chromatography mass-spectrometry (LC-MS)
The tryptic peptide mixture was separated by RP-UPLC
(ACQUITY, Waters, Manchester, UK) on a C18 column (BEH
C18 1,7 mm 2,16150 mm; Waters, Manchester, UK) and the
eluate online analyzed with a LTQ Orbitrap Velos electrospray
mass spectrometer (Thermo, Waltham, MA, US). The mobile
phases consisted of 0.1% formic acid in water (solvent A) and 0.1%
formic acid in acetonitrile (solvent B). The chromatography was
carried out using a gradient from 1 to 35% solvent B in 45 min
and finally from 35 to 80% solvent B in 3 min using a flow rate of
300 mL/min. UV absorption was measured at a wavelength of
Figure 6. Specific ion chromatograms (SICs) of Mab1 peptides containing LC-Asx-99/101. M=5464.46 Da (z=3, 4, and 5) (HC-Asp-99/101;
HC-iso-Asp-99/101) and M=5446.45 Da (z=3, 4, and 5) (HC-Asu-99/101) from the Mab1 reference material and a stressed sample (stored at 40uC for 2
month).
doi:10.1371/journal.pone.0030295.g006
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mass spectrometer were connected by PEEK-capillary tubes. Data
acquisition was controlled by XCalibure software (Thermo,
Waltham, MA). Parameters for MS detection were adjusted
according to general experience available from peptide analysis of
recombinant antibodies.
Data analysis for the quantification of deamidation/
isomerization levels
Peptides of interest were identified manually by searching their
m/z-values within the experimental mass spectrum. For the
quantification, specific ion current(SIC) chromatograms of peptides
of interest were generated on the basis of their monoisotopic mass
for all detectable charge states using GRAMS AI software (Thermo
Fisher Scientific, Dreieich, Germany). Relative amounts of Asn
deamidation and Asp isomerization were calculated by manual
integrationofmodified andunmodifiedpeptidepeaks.Forexample,
therelativecontentofLC-Asu-30(Tables1,2,3)iscalculatedbythe
integrated SIC chromatogram area of LC-Asu-30 divided by the
sum area of all LC-Asn-30 peptide species (LC-Asn-30, LC-Asu-30,
LC-Asp-30, and LC-isoAsp-30).
Identification of peptides by LC-MS/MS
MS/MS experiments were performed on-line on a Q-TOF
SYNAPT G2 instrument (Waters, Manchester, UK) using the
described chromatographic system. Peptides of interest were
isolated on the basis of their mass and charge state and
fragmentation induced by low-energy CID using helium as
collision gas. The collision energy was adjusted according to
stability and mass of the parent ion. Data acquisition was
controlled by MassLynx software (Waters, Manchester, UK) using
a manual acquisition mode. MS/MS-data were analyzed
manually using MassLynx software for mass detection and data
interpretation.
NanoESI-QTOF MS of HER2 and Mab1
Mass spectrometric analysis of reduced antibody light and heavy
chains was performed on a NanoESI-QTOF system (Q-TOF
Ultima, Waters, Manchester, UK). The spectra were recorded in
the positive ion mode using acetonitrile/water/formic acid (79/
20/1, v/v/v) as solvent.
Cation exchange chromatography (CEC)
Ion exchange chromatography was performed to monitor Mab1
charge variants using a ProPac WCX-10 Analytical cation
exchange column (4.06250 mm; Dionex Softron GmbH, Ger-
mering, Germany). A step gradient using 20 mM MES, pH 6.2 as
solvent A and 20 mM MES, 750 mM NaCl, pH 6.2 as solvent B
at 1.0 mL/min was applied. Chromatographic separation was
executed on an Ultimate3000 HPLC-system equipped with UV
detection at 280 nm. 50 mg mAb pre-treated with Carboxypep-
Figure 7. Specific ion chromatograms (SICs) of Mab1 peptides containing LC-Asx-56. M=841.47 Da (z=1, and 2) (LC-Asp-56; LC-iso-Asp-
56) and M=823.46 Da (z=1, and 2) (LC-Asu-56) from the Mab1 reference material and a stressed sample (stored at 40uC for 2 month).
doi:10.1371/journal.pone.0030295.g007
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containing Asp-56 (upper panel) and Asu-56 (lower panel) at m/z 421.7 and 412.7.
doi:10.1371/journal.pone.0030295.g008
Figure 9. Analysis of Mab1 target binding by surface plasmon resonance. Biacore sensorgrams showing the target binding of non-stressed
Mab1 material (stored at 280uC) and following elevated temperatures (storage at 40uC for 7 days, 1 month, and 2 month) at a flow rate of 100 ml/min.
doi:10.1371/journal.pone.0030295.g009
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chromatographic analysis.
Size exclusion chromatography (SEC)
Size exclusion chromatography was carried out using a TSK-
Gel G3000SWXL column (7.86300 mm, 5 mm particle size;
Tosoh Bioscience, Amsterdam, Netherlands). An isocratic elution
using 200 mM KH2PO4, 250 mM KCl, pH 7.0 at 0.5 mL/min as
solvent was used for chromatographic separation on an Ulti-
mate3000 HPLC-system equipped with UV detection at 280 nm.
150 mg of mAb was injected for the chromatographic analysi and
data acquisition was controlled by Chromeleon software (Dionex
Softron GmbH, Germering, Germany). Relative quantification
was performed by manual integration and comparison of peak
areas.
Analysis of target binding by surface plasmon resonance
(SPR)
The interaction between the stressed or non-stressed mAb and
the specific target protein was measured by surface plasmon
resonance using a Biacore T100 instrument (GE Healthcare
Bioscience, Uppsala, Sweden). To evaluate MAb interaction to its
specific target, the assay type ‘‘Calibration-free Concentration
analysis’’ (BiaEvaluation Software, GE Healthcare Bioscience,
Uppsala, Sweden) was performed. The specific target protein was
immobilized onto a Biacore CM5-biosensor chip (GE Healthcare
Bioscience, Uppsala, Sweden) via amine coupling to reach
maximum coupling density. The assay was carried out at room
temperature with HBS-P-buffer (GE Healthcare Bioscience) as
running and dilution buffer. 20 nM of native or stressed MAb
samples were injected at a flow rate of 5 mL/min and 100 mL/min
at room temperature, respectively. Association time was 90 s,
dissociation phase took 30 s. Regeneration of the chip surface was
reached by a short injection of 4 M MgCl2. Evaluation of SPR-
data was performed by comparison of the biological active amount
of an non-stressed sample with stressed samples. Biological activity
of non-stressed samples was set to 100%.
Acknowledgments
We are indebted to all members of the Laboratories in Penzberg for
valuable discussions.
Author Contributions
Conceived and designed the experiments: PB KD KB. Performed the
experiments: KD KB MW BZ AP TS RM BM JOS DR. Analyzed the
data: PB KD KB MM. Contributed reagents/materials/analysis tools: PB
DR. Wrote the paper: PB MM.
References
1. Yang H, Zubarev RA (2010) Mass spectrometric analysis of asparagine
deamidation and aspartate isomerization in polypeptides. Electrophoresis 31:
1764–1772.
2. Vlasak J, Ionescu R (2008) Heterogeneity of monoclonal antibodies revealed by
charge-sensitive methods. Curr Pharm Biotechnol 9: 468–481.
3. Wakankar AA, Borchardt RT (2006) Formulation considerations for proteins
susceptible to asparagine deamidation and aspartate isomerization. J Pharm Sci
95: 2321–2336.
4. Shimizu T, Matsuoka Y, Shirasawa T (2005) Biological significance of
isoaspartate and its repair system. Biol Pharm Bull 28: 1590–1596.
5. Lowenson J, Clarke S (1988) Does the chemical instability of aspartyl and
asparaginyl residues in proteins contribute to erythrocyte aging? The role of
protein carboxyl methylation reactions. Blood Cells 14: 103–118.
6. Harris RJ (2005) Heterogeneity of recombinant antibodies: linking structure to
function. Dev Biol (Basel) 122: 117–127.
7. Flatmark T, Sletten K (1968) Multiple forms of cytochrome c in the rat.
Precursor-product relationship between the main component Cy I and the
minor components Cy II and Cy 3 in vivo. J Biol Chem 243: 1623–1629.
8. Harding JJ, Beswick HT, Ajiboye R, Huby R, Blakytny R, et al. (1989) Non-
enzymic post-translational modification of proteins in aging. A review. Mech
Ageing Dev 50: 7–16.
9. Cacia J, Keck R, Presta LG, Frenz J (1996) Isomerization of an aspartic acid
residue in the complementarity-determining regions of a recombinant antibody
to human IgE: identification and effect on binding affinity. Biochemistry 35:
1897–1903.
10. Paborji M, Pochopin NL, Coppola WP, Bogardus JB (1994) Chemical and
physical stability of chimeric L6, a mouse-human monoclonal antibody. Pharm
Res 11: 764–771.
11. Kroon DJ, Baldwin-Ferro A, Lalan P (1992) Identification of sites of degradation
in a therapeutic monoclonal antibody by peptide mapping. Pharm Res 9:
1386–1393.
12. Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, et al. (2001)
Identification of multiple sources of charge heterogeneity in a recombinant
antibody. J Chromatogr B Biomed Sci Appl 752: 233–245.
13. Huang L, Lu J, Wroblewski VJ, Beals JM, Riggin RM (2005) In vivo
deamidation characterization of monoclonal antibody by LC/MS/MS. Anal
Chem 77: 1432–1439.
14. Yan B, Steen S, Hambly D, Valliere-Douglass J, Vanden Bos T, et al. (2009)
Succinimide formation at Asn 55 in the complementarity determining region of
a recombinant monoclonal antibody IgG1 heavy chain. J Pharm Sci 98:
3509–3521.
15. Chu GC, Chelius D, Xiao G, Khor HK, Coulibaly S, et al. (2007) Accumulation
of succinimide in a recombinant monoclonal antibody in mildly acidic buffers
under elevated temperatures. Pharm Res 24: 1145–1156.
16. Chelius D, Rehder DS, Bondarenko PV (2005) Identification and characteriza-
tion of deamidation sites in the conserved regions of human immunoglobulin
gamma antibodies. Anal Chem 77: 6004–6011.
17. Ota IM, Ding L, Clarke S (1987) Methylation at specific altered aspartyl and
asparaginyl residues in glucagon by the erythrocyte protein carboxyl
methyltransferase. J Biol Chem 262: 8522–8531.
18. Potter SM, Henzel WJ, Aswad DW (1993) In vitro aging of calmodulin generates
isoaspartate at multiple Asn-Gly and Asp-Gly sites in calcium-binding domains
II, III, and IV. Protein Sci 2: 1648–1663.
19. Kwong MY, Harris RJ (1994) Identification of succinimide sites in proteins by
N-terminal sequence analysis after alkaline hydroxylamine cleavage. Protein Sci
3: 147–149.
20. Teshima G, Stults JT, Ling V, Canova-Davis E (1991) Isolation and
characterization of a succinimide variant of methionyl human growth hormone.
J Biol Chem 266: 13544–13547.
21. Cournoyer JJ, Pittman JL, Ivleva VB, Fallows E, Waskell L, et al. (2005)
Deamidation: Differentiation of aspartyl from isoaspartyl products in peptides by
electron capture dissociation. Protein Sci 14: 452–463.
22. Schmid DG, von der Mulbe FD, Fleckenstein B, Weinschenk T, Jung G (2001)
Broadband detection electrospray ionization Fourier transform ion cyclotron
resonance mass spectrometry to reveal enzymatically and chemically induced
deamidation reactions within peptides. Anal Chem 73: 6008–6013.
23. Zabrouskov V, Han X, Welker E, Zhai H, Lin C, et al. (2006) Stepwise
deamidation of ribonuclease A at five sites determined by top down mass
spectrometry. Biochemistry 45: 987–992.
24. Robinson NE, Zabrouskov V, Zhang J, Lampi KJ, Robinson AB (2006)
Measurement of deamidation of intact proteins by isotopic envelope and mass
defect with ion cyclotron resonance Fourier transform mass spectrometry. Rapid
Commun Mass Spectrom 20: 3535–3541.
25. Carr SA, Hemling ME, Bean MF, Roberts GD (1991) Integration of mass
spectrometry in analytical biotechnology. Anal Chem 63: 2802–2824.
26. Xiao G, Bondarenko PV, Jacob J, Chu GC, Chelius D (2007) 18O labeling
method for identification and quantification of succinimide in proteins. Anal
Chem 79: 2714–2721.
27. Huang HZ, Nichols A, Liu D (2009) Direct identification and quantification of
aspartyl succinimide in an IgG2 mAb by RapiGest assisted digestion. Anal
Chem 81: 1686–1692.
28. Timm V, Gruber P, Wasiliu M, Lindhofer H, Chelius D (2010) Identification
and characterization of oxidation and deamidation sites in monoclonal rat/
mouse hybrid antibodies. J Chromatogr B Analyt Technol Biomed Life Sci 878:
777–784.
29. Zhang J, Yip H, Katta V (2011) Identification of isomerization and racemization
of aspartate in the Asp-Asp motifs of a therapeutic protein. Anal Biochem 410:
234–243.
30. Yu XC, Joe K, Zhang Y, Adriano A, Wang Y, et al. (2011) Accurate
Determination of Succinimide Degradation Products Using High Fidelity
Trypsin Digestion Peptide Map Analysis. Anal Chem 83: 5912–5919.
31. Hensel M, Steurer R, Fichtl J, Elger C, Wedekind F, et al. (2011) Identification
of potential sites for tryptophan oxidation in recombinant antibodies using tert-
butylhydroperoxide and quantitative LC-MS. PLoS One 6: e17708.
Assessment of mAb Isomerization and Deamidation
PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e30295